"Pfizer's Q4 Earnings: New Drugs Boost Sales and Drive Stock Growth"

Pfizer's Q4 earnings are expected to reflect the impact of newly launched and acquired drugs, including Abrysvo, Velsipity, Penbraya, Zavzpret, Nurtec, Oxbryta, and Seagen's ADCs. While COVID-19 product revenues may have declined, sales from non-COVID products like Vyndaqel/Vyndamax and Prevnar family of vaccines, as well as newly acquired products, are likely to provide support. Investors are keen to know the sales numbers of these products, with estimates for Abrysvo, Nurtec, and Oxbryta at $510 million, $246 million, and $94.5 million, respectively. Pfizer's stock has declined, and it holds a Zacks Rank #5 (Strong Sell), while Regeneron Pharmaceuticals and Novo Nordisk are considered better-ranked alternatives.